Literature DB >> 2243114

Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194.

D P Williams1, Z Wen, R S Watson, J Boyd, T B Strom, J R Murphy.   

Abstract

We have used site-directed mutagenesis to examine the role played by Arg191, Arg193, and Arg194 of the fusion toxin DAB486-IL-2 in the intoxication of high affinity interleukin-2 receptor-bearing T-lymphocytes. These arginine residues are positioned in the proteolytically sensitive 14-amino acid loop subtended by the disulfide bond between Cys187 and Cys202 in this fusion toxin. DAB486-IL-2 was formed by the genetic substitution of the native diphtheria toxin receptor binding domain with human interleukin-2 (Williams, D.P., Parker, K., Bacha, P., Bishai, W., Borowski, M., Genbauffe, F., Strom, T.B., and Murphy, J.R. (1987) Protein Eng. 1, 493-498). We demonstrate that substitution of Arg194 with Gly results in a 1000-fold loss of DAB486-IL-2 potency. Since trypsin "nicking" of the Gly194 mutant restores biologic activity, we conclude that Arg194 is required for the cellular processing of the fusion toxin which results in the release of fragment A into the cytosol.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2243114

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Localization of diphtheria toxin nuclease activity to fragment A.

Authors:  S L Lessnick; J B Lyczak; C Bruce; D G Lewis; P S Kim; M L Stolowitz; L Hood; B J Wisnieski
Journal:  J Bacteriol       Date:  1992-03       Impact factor: 3.490

Review 2.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

3.  2006 Homer W. Smith Lecture: taming T cells.

Authors:  Terry B Strom
Journal:  J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 10.121

Review 4.  Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases.

Authors:  V M Gordon; S H Leppla
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

5.  Identification of a single amino acid substitution in the diphtheria toxin A chain of CRM 228 responsible for the loss of enzymatic activity.

Authors:  V G Johnson; P J Nicholls
Journal:  J Bacteriol       Date:  1994-08       Impact factor: 3.490

6.  DAB389IL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice.

Authors:  Mahendra K Bhopale; Brendan Hilliard; Cris S Constantinescu; S Michael Phillips; Abdolmohamad Rostami
Journal:  Immunopharmacol Immunotoxicol       Date:  2017-09-20       Impact factor: 2.730

7.  Ontak-like human IL-2 fusion toxin.

Authors:  Zhaohui Wang; Qian Zheng; Huiping Zhang; Roderick T Bronson; Joren C Madsen; David H Sachs; Christene A Huang; Zhirui Wang
Journal:  J Immunol Methods       Date:  2017-05-24       Impact factor: 2.303

8.  Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells.

Authors:  Jaclyn Stromp Peraino; Huiping Zhang; Priyani V Rajasekera; Min Wei; Joren C Madsen; David H Sachs; Christene A Huang; Zhirui Wang
Journal:  J Immunol Methods       Date:  2014-01-24       Impact factor: 2.303

9.  Sensitivity of cancer cells to truncated diphtheria toxin.

Authors:  Yi Zhang; Wendy Schulte; Desmond Pink; Kyle Phipps; Andries Zijlstra; John D Lewis; David Morton Waisman
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

Review 10.  Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.